Imprimis Pharma (IMMY) Reports Q4 Revenues Above Estimates

Note: EPS may not be comparable

Imprimis Pharma (NASDAQ: IMMY) reported Q4 revenue for the quarter came in at $7.3 million versus the consensus estimate of $6.86 million.

Notable Highlights:

• Revenue of $7.3 million, up 27% year-over-year
• Gross ophthalmology-related revenue of $5.8 million, up 64% year-over-year
• Average 503B order exceeded $1,400 for the quarter
• Gross Margin of 53%, compared to 47% in Q4 2016
• Adjusted EBITDA loss of $794,000, a 67% improvement year-over-year, and 52% improvement quarter-over-quarter
• There are 8 clinical studies and investigations underway or near completion on the MKO Melt®, LessDrops®, OmegaDoxy™, Simple Drops™ and Imprimis\'s patent-pending cyclosporine formulations

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Mercury Systems (MRCY) Misses Q4 EPS by 2c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance